Drug Profile
RUS 350
Alternative Names: RUS350Latest Information Update: 18 Jul 2018
Price :
$50
*
At a glance
- Originator Cambridge Laboratories
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Huntington's disease
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 28 Sep 2010 Biovail Corporation merged with Valeant Pharmaceuticals International forming Valeant Pharmaceuticals International
- 22 May 2009 Phase-I clinical trials in Huntington's disease in United Kingdom (PO)